| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ... Cancer treatment reviews 41 (2), 114-121, 2015 | 463 | 2015 |
| Metabolic phenotype of bladder cancer F Massari, C Ciccarese, M Santoni, R Iacovelli, R Mazzucchelli, F Piva, ... Cancer treatment reviews 45, 46-57, 2016 | 244 | 2016 |
| The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer R Iacovelli, C Ciccarese, E Bria, M Romano, E Fantinel, D Bimbatti, ... Clinical genitourinary cancer 16 (3), e645-e653, 2018 | 161 | 2018 |
| Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance S Grisanti, C Almici, F Consoli, M Buglione, R Verardi, A Bolzoni-Villaret, ... PloS one 9 (8), e103918, 2014 | 95 | 2014 |
| Metabolic alterations in renal cell carcinoma F Massari, C Ciccarese, M Santoni, M Brunelli, F Piva, A Modena, ... Cancer treatment reviews 41 (9), 767-776, 2015 | 88 | 2015 |
| Emerging concepts on drug resistance in bladder cancer: Implications for future strategies F Massari, M Santoni, C Ciccarese, M Brunelli, A Conti, D Santini, ... Critical reviews in oncology/hematology 96 (1), 81-90, 2015 | 85 | 2015 |
| Prostate cancer heterogeneity: Discovering novel molecular targets for therapy C Ciccarese, F Massari, R Iacovelli, M Fiorentino, R Montironi, ... Cancer Treatment Reviews 54, 68-73, 2017 | 84 | 2017 |
| Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis F Massari, C Ciccarese, A Calio, E Munari, L Cima, AB Porcaro, G Novella, ... Targeted oncology 11, 345-351, 2016 | 81 | 2016 |
| Immune checkpoint inhibitors and prostate cancer: a new frontier? A Modena, C Ciccarese, R Iacovelli, M Brunelli, R Montironi, M Fiorentino, ... Oncology reviews 10 (1), 2016 | 72 | 2016 |
| The prospect of precision therapy for renal cell carcinoma C Ciccarese, M Brunelli, R Montironi, M Fiorentino, R Iacovelli, D Heng, ... Cancer Treatment Reviews 49, 37-44, 2016 | 66 | 2016 |
| AR-V7 and prostate cancer: The watershed for treatment selection? C Ciccarese, M Santoni, M Brunelli, S Buti, A Modena, M Nabissi, ... Cancer treatment reviews 43, 27-35, 2016 | 66 | 2016 |
| Role of STAT3 pathway in genitourinary tumors M Santoni, A Conti, F Piva, F Massari, C Ciccarese, L Burattini, L Cheng, ... Future Science Oa 1 (3), FSO15, 2015 | 64 | 2015 |
| Patients with sarcomatoid renal cell carcinoma–Re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors R Iacovelli, C Ciccarese, E Bria, S Bracarda, C Porta, G Procopio, ... European Journal of Cancer 136, 195-203, 2020 | 62 | 2020 |
| New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors C Ciccarese, S Alfieri, M Santoni, D Santini, M Brunelli, C Bergamini, ... Expert opinion on drug metabolism & toxicology 12 (1), 57-75, 2016 | 59 | 2016 |
| Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer M Santoni, F Massari, M Del Re, C Ciccarese, F Piva, G Principato, ... Expert opinion on investigational drugs 24 (6), 809-824, 2015 | 54 | 2015 |
| De novo metastatic castration sensitive prostate cancer: State of art and future perspectives C Mosillo, R Iacovelli, C Ciccarese, E Fantinel, D Bimbatti, M Brunelli, ... Cancer Treatment Reviews 70, 67-74, 2018 | 50 | 2018 |
| Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies C Ciccarese, R Iacovelli, M Brunelli, F Massari, D Bimbatti, E Fantinel, ... European Journal of Cancer 83, 237-246, 2017 | 43 | 2017 |
| Revising PTEN in the era of immunotherapy: new perspectives for an old story G Piro, C Carbone, L Carbognin, S Pilotto, C Ciccarese, R Iacovelli, ... Cancers 11 (10), 1525, 2019 | 39 | 2019 |
| Adjuvant therapy in renal cell carcinoma F Massari, V Di Nunno, C Ciccarese, J Graham, C Porta, F Comito, ... Cancer treatment reviews 60, 152-157, 2017 | 39 | 2017 |
| Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis R Iacovelli, C Ciccarese, G Facchini, M Milella, F Urbano, U Basso, ... Targeted Oncology 15, 495-501, 2020 | 35 | 2020 |
